Search

Your search keyword '"Costa-Frossard, L."' showing total 165 results

Search Constraints

Start Over You searched for: Author "Costa-Frossard, L." Remove constraint Author: "Costa-Frossard, L."
165 results on '"Costa-Frossard, L."'

Search Results

1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

2. Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023

3. Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study

7. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

8. Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español

9. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

10. 21131. MICRORNAS Y NIVELES DE CADENA LIGERA DE NEUROFILAMENTOS ASOCIADOS CON VARIABLES CLÍNICAS Y RADIOLÓGICAS EN PACIENTES CON ESCLEROSIS MÚLTIPLE

12. 20486. BÚSQUEDA DE NUEVOS BIOMARCADORES A TRAVÉS DEL ESTUDIO DE LOS NIVELES DE PROTEÍNAS INFLAMATORIAS EN MUESTRAS DE SUERO DE PACIENTES DE ESCLEROSIS MÚLTIPLE NO TRATADOS

13. 20485. ÁCIDOS GRASOS DE CADENA CORTA EN PACIENTES DE ESCLEROSIS MÚLTIPLE: ESTUDIO DE SU ASOCIACIÓN CON LA ACTIVIDAD Y LA PROGRESIÓN DE LA ENFERMEDAD

15. 21185. SUSPENSIÓN DE TRATAMIENTO MODIFICADOR DE LA ENFERMEDAD EN PACIENTES CON ESCLEROSIS MÚLTIPLE: ESTUDIO RETROSPECTIVO

16. 20403. NIVELES SÉRICOS DE NEUROFILAMENTOS DE CADENA LIGERA COMO FACTOR PREDICTOR DE RESPUESTA EN UNA COHORTE MULTICÉNTRICA DE PACIENTES CON ESCLEROSIS MÚLTIPLE TRATADOS CON OCRELIZUMAB

23. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis

24. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

25. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I)

26. Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español

27. Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis

28. Recomendaciones para la coordinación de los servicios de Neurología y Neurorradiología en la atención a pacientes con esclerosis múltiple

29. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

30. Clinical usefulness of prognostic biomarkers in optic neuritis

31. Manejo de los sintomas asociados a la espasticidad en pacientes con esclerosis multiple

32. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

33. Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab

35. Efectividad de la lacosamida en el tratamiento del dolor neuropático refractario: estudio observacional abierto

40. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat

41. Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

42. Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.

43. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

44. A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.

45. Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

46. Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

47. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

48. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

49. Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis.

50. Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.

Catalog

Books, media, physical & digital resources